
HealthMore in Health→
Pfizer Secures Obesity Drug Approval in China
Key Takeaways
- Pfizer wins China approval for GLP-1 obesity shot licensed from Sciwind
- Enters market where obesity affects over half of Chinese adults
- Licensing approach fast-tracks entry against established rivals Novo and Lilly
DE
DT Editorial Team··3 min read·via endpoints.news

